|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Monoamine_oxidase_inhibitors
|
|
gptkbp:activities
|
inhibits monoamine oxidase
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1959
gptkb:FDA
|
|
gptkbp:brand
|
Nardil
|
|
gptkbp:class
|
gptkb:drug
hydrazine derivative
|
|
gptkbp:clinical_trial
|
depression treatment
anxiety treatment
|
|
gptkbp:composed_of
|
reduction of phenylhydrazine
|
|
gptkbp:contraindication
|
gptkb:pheochromocytoma
liver disease
heart disease
history of stroke
|
|
gptkbp:developed_by
|
gptkb:Parke-Davis
|
|
gptkbp:dosage_form
|
15 to 90 mg per day
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenelzine
|
|
gptkbp:ingredients
|
C12 H12 N2 O3
|
|
gptkbp:interacts_with
|
tyramine
opioids
stimulants
certain antidepressants
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
gptkb:historical_event
anxiety disorders
|
|
gptkbp:lifespan
|
11 to 16 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
mental health treatment
MAO inhibitors
psychotropic drugs
antidepressant medications
neurotransmitter modulation
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:side_effect
|
dizziness
nausea
seizures
insomnia
dry mouth
weight gain
hypertensive crisis
sexual dysfunction
peripheral edema
serotonin syndrome
|
|
gptkbp:type_of
|
51-71-8
|
|
gptkbp:year_created
|
1950s
|